From: Evaluation of clinical efficacy, adverse reactions, and safety of PD-1 inhibitors combined with chemotherapy when treating advanced gastric cancer
Research group
Control group
P
Myelosuppression (case, %)
6 (13.3%)
7 (15.6%)
1.000
Hypothyroidism (case, %)
5 (11.1%)
0.756
High blood pressure (case, %)
Dermatotoxicity (case, %)